Literature DB >> 22461185

Circulating angiopoietin and Tie-2 levels in systemic sclerosis.

James V Dunne1, Kevin J Keen, Stephan F Van Eeden.   

Abstract

To determine the potential effects of angiopoietins Ang-1 and Ang-2 and their receptor Tie-2 in patients with systemic sclerosis (SSc). Twenty-six patients with limited SSc (l-SSc) and fourteen patients with diffuse SSc (d-SSc) were evaluated and compared to age-matched controls. Plasma levels of soluble sAng-1, sAng-2, sTie-2, vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and endostatin were measured. Associations between these factors and clinical parameters were assessed. Levels of circulating factors and the ratios sAng-2/sAng-1 and sAng-2/sTie-2 were not different between l-SSc and d-SSc cases but were collectively higher compared to their controls: sAng-1 (p = 0.0108); sAng-2 (p < 0.0001); sTie-2 (p < 0.0001); endostatin (p < 0.0001), PlGF (p < 0.0001); VEGF (p = 0.0006); sAng-2/sAng-1 (p < 0.0001); sAng-2/sTie-2 (p < 0.0001). Concerning significant correlations among the angiopoietins and Tie-2, sAng-2 associated with sTie-2 (Spearman r = 0.47, p = 0.0155) in l-SSc only. sAng-1 did not show statistically significant correlations with any of the clinical variables, but sAng-2 did between PAP (r = 0.51, p = 0.0148) and predicted DLCO (r = -0.31, p = 0.0242) in l-SSc cases. sTie-2 negatively correlated with disease duration in l-SSc (r = -0.55, p = 0.0049). The sAng-2/sTie-2 ratio shows a positive association with disease activity in both l-SSc (r = 0.50, p = 0.0547) and d-SSc (r = 0.60, p = 0.0317). Levels of sAng-1, sAng-2 and sTie-2 are higher in SSc cases suggesting a pro-inflammatory state in an active endothelium. The near doubling of the sAng-2/sTie-2 ratio in SSc cases compared to controls suggests a shift toward vascular regression and angiostasis perhaps caused by Ang-2 blocking the action of Tie-2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461185     DOI: 10.1007/s00296-012-2378-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  47 in total

1.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

2.  Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.

Authors:  A L Harris; P Reusch; B Barleon; C Hang; N Dobbs; D Marme
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

3.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

4.  Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells.

Authors:  Christopher Daly; Elizabeth Pasnikowski; Elena Burova; Vivian Wong; Thomas H Aldrich; Jennifer Griffiths; Ella Ioffe; Thomas J Daly; James P Fandl; Nick Papadopoulos; Donald M McDonald; Gavin Thurston; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

5.  Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease.

Authors:  Malgorzata Michalska-Jakubus; Otylia Kowal-Bielecka; Grazyna Chodorowska; Marek Bielecki; Dorota Krasowska
Journal:  Rheumatology (Oxford)       Date:  2010-12-10       Impact factor: 7.580

6.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Authors:  D Maglione; V Guerriero; G Viglietto; P Delli-Bovi; M G Persico
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.

Authors:  Clarence M Findley; Robert G Mitchell; Brian D Duscha; Brian H Annex; Christopher D Kontos
Journal:  J Am Coll Cardiol       Date:  2008-07-29       Impact factor: 24.094

Review 10.  Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.

Authors:  Mirko Manetti; Serena Guiducci; Lidia Ibba-Manneschi; Marco Matucci-Cerinic
Journal:  J Cell Mol Med       Date:  2010-01-30       Impact factor: 5.310

View more
  8 in total

Review 1.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

2.  Acroosteolysis in systemic sclerosis: An insight into hypoxia-related pathogenesis.

Authors:  Simon Siao-Pin; Laura-Otilia Damian; Laura Mirela Muntean; Simona Rednic
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

Review 3.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

4.  L-selectin and skin damage in systemic sclerosis.

Authors:  James V Dunne; Stephan F van Eeden; Kevin J Keen
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 5.  Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.

Authors:  Alsya J Affandi; Timothy R D J Radstake; Wioleta Marut
Journal:  Semin Immunopathol       Date:  2015-07-14       Impact factor: 9.623

6.  Tie2 as a novel key factor of microangiopathy in systemic sclerosis.

Authors:  Falk Moritz; Janine Schniering; Jörg H W Distler; Renate E Gay; Steffen Gay; Oliver Distler; Britta Maurer
Journal:  Arthritis Res Ther       Date:  2017-05-25       Impact factor: 5.156

7.  Serum markers of cardiac complications in a systemic sclerosis cohort.

Authors:  Anders H Tennøe; Klaus Murbræch; Henriette Didriksen; Thor Ueland; Vyacheslav Palchevskiy; Stephen S Weigt; Håvard Fretheim; Øyvind Midtvedt; Torhild Garen; Cathrine Brunborg; Pål Aukrust; Øyvind Molberg; John A Belperio; Anna-Maria Hoffmann-Vold
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

8.  Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis.

Authors:  Agathe Leblond; Sonia Pezet; Anne Priscille Trouvin; Muriel Elhai; Virginie Gonzalez; Yannick Allanore; Jérôme Avouac
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.